Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang 524023, China.
First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
Biomed Pharmacother. 2021 Feb;134:111103. doi: 10.1016/j.biopha.2020.111103. Epub 2020 Dec 15.
Nanomedicines offer nanoscale drug delivery system. They offer ways of promising drug transportation, and address the issues of lack of targeting and permeability of traditional drugs. The physical and chemical properties in the domain of nanomedicine applications in vivo have not been sufficiently delivered. What's more, the metabolic of nanomedicines is not clear enough. Those factors which mentioned above determine that many nanomedicines have not yet realized clinical application due to their safety problems and in vivo efficacy. For example, they may cause immune response and cytotoxicity, as well as the ability to clear organs in vivo, the penetration ability of them and the lack of targeting ability may also cause poor efficacy of drugs in vivo. In this review, the new progresses of different kinds of nanomedicines (including gold nanoparticles, nanorobots, black phosphorus nanoparticles, brain diseases, gene editing and immunotherapy etc.) in anti-tumor, antibacterial, ocular diseases and arteriosclerosis in recent years were summarized. Their shortcomings were pointed out, and the new methods to improve the biosafety and efficacy were summarized.
纳米医药提供了纳米级药物输送系统。它们提供了有前途的药物运输方式,并解决了传统药物靶向性和通透性不足的问题。纳米医药应用领域的物理和化学性质在体内还没有得到充分的传递。更重要的是,纳米医药的代谢过程还不够清楚。由于安全性问题和体内疗效问题,上述因素决定了许多纳米医药尚未实现临床应用。例如,它们可能引起免疫反应和细胞毒性,以及体内清除器官的能力、它们的穿透能力和缺乏靶向能力也可能导致药物在体内的疗效不佳。在这篇综述中,总结了近年来不同类型的纳米医药(包括金纳米粒子、纳米机器人、黑磷纳米粒子、脑疾病、基因编辑和免疫疗法等)在抗肿瘤、抗菌、眼部疾病和动脉硬化方面的新进展。指出了它们的缺点,并总结了提高生物安全性和疗效的新方法。